Dupilumab
Red
Brand:
Dupixent®
Nice TA:
534
Commissioning responsibility:
CCG
PbR excluded:
Yes
BNF chapter:
Skin
Background
Dupilumab is recommended as an option for treating moderate to severe atopic dermatitis in adults, only if:
-
the disease has not responded to at least 1 other systemic therapy, such as ciclosporin, methotrexate, azathioprine and mycophenolate mofetil, or these are contraindicated or not tolerated
-
the company provides dupilumab according to the commercial arrangement.
Stop dupilumab at 16 weeks if the atopic dermatitis has not responded adequately. An adequate response is:
-
at least a 50% reduction in the Eczema Area and Severity Index score (EASI 50) from when treatment started and
-
at least a 4‑point reduction in the Dermatology Life Quality Index (DLQI) from when treatment started